caa a22 4500 46320056X CHVBK 20180405153111.0 cr unu---uuuuu 170326e20070501xx s 000 0 eng 10.1007/s10014-006-0209-6 doi (NATIONALLICENCE)springer-10.1007/s10014-006-0209-6 FISH 1p/19q deletion/imbalance for molecular subclassification of glioblastoma [Elektronische Daten] [Toru Nagasaka, Masaharu Gunji, Noboru Hosokai, Kumiko Hayashi, Hiroshi Ikeda, Masafumi Ito, Suguru Inao] Glioblastoma is the most malignant and frequent of the glial tumors. A minor fraction of glioblastoma may contain areas showing oligodendroglioma-like tumor cell differentiation. Several authors have described such tumors as glioblastoma with oligodendroglial component (GBMO). GBMO may represent the ultimate level of malignancy in the oligodendroglial lineage. The oligodendroglial component and combined loss of chromosomal arm 1p and 19q in glioblastoma indicate increased survival. In our study, we analyzed 1p and 19q status in a series of 12 glioblastoma and 8 oligodendroglial tumors using fluorescence in situ hybridization (FISH) on paraffin-embedded tissues. In each case, hybridization status was classified as deletion, imbalance, polysomy, amplification, or normal pattern. Other genetic alterations such as CDKN2A (p16), RB, and EGFR were also assessed. On histological review, 2 of 12 glioblastoma (16.7%) were classified as GBMO. Chromosome 1p/19q deletion was detected in 3 of 12 glioblastomas (25%). In contrast, all 8 oligodendroglial tumors showed 1p/19q deletion. All GBMO had 19q deletion with imbalance, whereas 1 of 10 ordinary glioblastoma (10%) demonstrated 19q deletion with imbalance. All but 1 ordinary glioblastoma (90%) showed CDKN2A (p16) deletion, but no GBMO displayed this alteration. Our results indicate that GBMO may be a distinct subtype of glioblastoma harboring a characteristic molecular profile. FISH on paraffin-embedded specimens is a useful method for subclassification of glioblastoma. The Japan Society of Brain Tumor Pathology, 2007 Glioblastoma nationallicence Oligodendroglioma nationallicence Fluorescence in situ hybridization nationallicence 1p/19q imbalance nationallicence CDKN2A deletion nationallicence Nagasaka Toru Department of Neurosurgery, Japanese Red Cross Nagoya First Hospital, 3-35 Michishita-cho, Nakamura-ku, 453-8511, Nagoya, Japan aut Gunji Masaharu Department of Pathology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan aut Hosokai Noboru Mitsubishi Kagaku Bio-Clinical Laboratories, Inc., Tokyo, Japan aut Hayashi Kumiko Mitsubishi Kagaku Bio-Clinical Laboratories, Inc., Tokyo, Japan aut Ikeda Hiroshi Department of Neurosurgery, Japanese Red Cross Nagoya First Hospital, 3-35 Michishita-cho, Nakamura-ku, 453-8511, Nagoya, Japan aut Ito Masafumi Department of Pathology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan aut Inao Suguru Department of Neurosurgery, Japanese Red Cross Nagoya First Hospital, 3-35 Michishita-cho, Nakamura-ku, 453-8511, Nagoya, Japan aut Brain Tumor Pathology Springer-Verlag 24/1(2007-05-01), 1-5 1433-7398 24:1<1 2007 24 10014 https://doi.org/10.1007/s10014-006-0209-6 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10014-006-0209-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Nagasaka Toru Department of Neurosurgery, Japanese Red Cross Nagoya First Hospital, 3-35 Michishita-cho, Nakamura-ku, 453-8511, Nagoya, Japan aut NATIONALLICENCE 700 1- Gunji Masaharu Department of Pathology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan aut NATIONALLICENCE 700 1- Hosokai Noboru Mitsubishi Kagaku Bio-Clinical Laboratories, Inc., Tokyo, Japan aut NATIONALLICENCE 700 1- Hayashi Kumiko Mitsubishi Kagaku Bio-Clinical Laboratories, Inc., Tokyo, Japan aut NATIONALLICENCE 700 1- Ikeda Hiroshi Department of Neurosurgery, Japanese Red Cross Nagoya First Hospital, 3-35 Michishita-cho, Nakamura-ku, 453-8511, Nagoya, Japan aut NATIONALLICENCE 700 1- Ito Masafumi Department of Pathology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan aut NATIONALLICENCE 700 1- Inao Suguru Department of Neurosurgery, Japanese Red Cross Nagoya First Hospital, 3-35 Michishita-cho, Nakamura-ku, 453-8511, Nagoya, Japan aut NATIONALLICENCE 773 0- Brain Tumor Pathology Springer-Verlag 24/1(2007-05-01), 1-5 1433-7398 24:1<1 2007 24 10014 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer